Page 25 - Systemic Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update News provided by Share this article NASHVILLE, Tenn., May 11, 2021 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and first quarter 2021 financial results. Net revenues from continuing operations during the quarter were $10.5 million, a 26.5% increase over the prior year period. The company also recorded an additional $500,000 in revenue during the first quarter associated with divested product rights for two brands...

The Autoimmune Registry announces the "Cure the Mother's Disease" Fundraiser News provided by Share this article Share this article NEW HAVEN, Conn., May 5, 2021 The Autoimmune Registry (ARI) announces its "Cure the Mother's Disease" fundraiser to support research on innovative diagnostic tools being developed at the University of Kentucky.  Sydney Abend, a mother with Sjogren's Syndrome, told ARI, "For 10 years, I was told 'everyone has dry eyes' and 'you're just getting old'. I felt validated when I got my Sjogren's diagnosis.  Women are disproportionately affected by these diseases and...

Share this article Share this article TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). CM-101 is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity, an important chemokine activity that stimulates inflammation and the development of fibros...

(0) NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company's ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs. The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg twice daily (BID). The primary endpoint is the Combined Response Index for Systemic Sclerosis (CRISS)...

Chemomab Completes Merger with Anchiano Therapeutics USA - English Combined company will focus on advancing Chemomab's CM-101 currently in Phase 2 for rare fibrotic indications Company to receive gross proceeds of $45.5 Million from a PIPE financing, led by healthcare-focused investors Cormorant Asset Management, OrbiMed, Peter Thiel and Christian Angermayer's Presight Capital and Apeiron Investment Group News provided by Share this article Share this article TEL-AVIV, Israel, March. 16, 2021 /PRNewswire/ -- Chemomab Ltd., a clinical-stage biotech company focused on the discovery and developm...